MET and non-small cell lung carcinoma: Tepotinib (TEPMETKO, MSC2156119J, Table S1) is an oral, highly selective, potent type Ib ATP-competitive MET inhibitor, which has been approved in Japan and the USA for the treatment of adults with advanced or metastatic NSCLC harboring METex14 skipping alterations (21, 22, 23, 24, 25, 26).